申请人:Astrazeneca AB
公开号:EP2607357A1
公开(公告)日:2013-06-26
A compound of formula I
or a pharmaceutically acceptable salt thereof in which R1, R2, R3, R4 and m are as described in the specification for use in the treatment of obesity and/or diabetes.
式 I 的化合物
或其药学上可接受的盐,其中 R1、R2、R3、R4 和 m 如说明书所述,用于治疗肥胖症和/或糖尿病。